These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 17916172

  • 1. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
    Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P.
    Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Variation in the use of recombinant activated factor VII in critical bleeding.
    Willis CD, Cameron PA, Phillips L.
    Intern Med J; 2010 Jul; 40(7):486-93. PubMed ID: 19712199
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children.
    Herbertson M, Kenet G.
    Haemophilia; 2008 Jul; 14(4):753-62. PubMed ID: 18445016
    [Abstract] [Full Text] [Related]

  • 11. Investigation of outcomes following recombinant activated FVII use for refractory bleeding during abdominal aortic aneurysm repair.
    Kandane-Rathnayake RK, Willis CD, Beiles CB, Bourke BM, Cameron PA, McCall P, Phillips LE.
    Eur J Vasc Endovasc Surg; 2013 Jun; 45(6):617-25. PubMed ID: 23433950
    [Abstract] [Full Text] [Related]

  • 12. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
    Guzzetta NA, Russell IA, Williams GD.
    Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
    [Abstract] [Full Text] [Related]

  • 13. Safety of recombinant activated factor VII in randomized clinical trials.
    Levi M, Levy JH, Andersen HF, Truloff D.
    N Engl J Med; 2010 Nov 04; 363(19):1791-800. PubMed ID: 21047223
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.
    Zatta A, Mcquilten Z, Kandane-Rathnayake R, Isbister J, Dunkley S, Mcneil J, Cameron P, Phillips L.
    Blood Transfus; 2015 Jan 04; 13(1):86-99. PubMed ID: 24960661
    [Abstract] [Full Text] [Related]

  • 16. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
    Tomita E, Takase H, Tajima K, Suematsu Y.
    Asian Cardiovasc Thorac Ann; 2017 Feb 04; 25(2):99-104. PubMed ID: 28114794
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
    Palmason R, Vidarsson B, Sigvaldason K, Ingimarsson JP, Gudbjartsson T, Sigurdsson GH, Onundarson PT.
    Acta Anaesthesiol Scand; 2012 May 04; 56(5):636-44. PubMed ID: 22489992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.